Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 2/20 | 0.44 |
| ▸ | RORB | Q92753 | 2/20 | 0.44 |
| ▸ | TUBB4A | P04350 | 6/20 | 0.42 |
| ▸ | TUBB | P07437 | 6/20 | 0.42 |
| ▸ | TUBA3C | P0DPH7 | 6/20 | 0.42 |
| ▸ | TUBA1B | P68363 | 6/20 | 0.42 |
| ▸ | TUBA4A | P68366 | 6/20 | 0.42 |
| ▸ | TUBB4B | P68371 | 6/20 | 0.42 |
| ▸ | TUBB3 | Q13509 | 6/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4119074 | 0.85 | NPC1 (0.47) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL635552 | 0.85 | RECQL (0.56) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3762150 | 0.81 | RAB9A (0.55) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13502193 | 0.80 | MRGPRX4 (0.46) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4122687 | 0.80 | L3MBTL1 (0.44) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2350397 | 0.79 | POLB (0.49) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5520431 | 0.77 | MEN1 (0.49) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2705579 | 0.76 | SLC6A4 (0.54) | KDM4EALDH1A1NPC1SMN1; SMN2LMNA | |
| SCHEMBL8467508 | 0.76 | RAB9A (0.52) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4240157 | 0.75 | PPARG (0.46) | KDM4EALDH1A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016299-A1 | Substituted benzoxepino-isoxazoles and use thereof | BAYER HEALTHCARE AG (DE) | 2010-01-21 | — | — | US | disclosed |
| US-20100016299-A1 | Substituted benzoxepino-isoxazoles and use thereof | BAYER HEALTHCARE AG (DE) | 2010-01-21 | — | — | US | disclosed |
| US-20100016299-A1 | Substituted benzoxepino-isoxazoles and use thereof | BAYER HEALTHCARE AG (DE) | 2010-01-21 | — | — | US | disclosed |
| EP-2041144-A1 | SUBSTITUTED BENZOXEPINO-ISOXAZOLES AND USE THEREOF | Bayer HealthCare AG (DE) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008003424-A1 | SUBSTITUTED BENZOXEPINO-ISOXAZOLES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008003424-A1 | SUBSTITUTED BENZOXEPINO-ISOXAZOLES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016299-A1 | Substituted benzoxepino-isoxazoles and use thereof | BMX, CYP4X1, AGXT | KDM4E 1849/4885ALDH1A1 1783/4885NPC1 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.